Welcome!

News Feed Item

AgeneBio Appoints Industry Leaders Patrick LePore as Chairman of the Board and Jerry McLaughlin as President and Chief Executive Officer

Appointments Complete Leadership Team to Advance Development Programs Including a Product Candidate in Phase II/III to Slow the Progression of Alzheimer's Disease

BALTIMORE, MD -- (Marketwired) -- 07/25/14 -- AgeneBio, Inc., a clinical-stage pharmaceutical company developing medicines to restore and preserve patients' cognitive function for a range of debilitating neurodegenerative diseases, today announced the appointment of Patrick LePore as chairman of the board and Jerry McLaughlin as president and chief executive officer. Both appointments are effective immediately.

"Pat and Jerry are distinguished leaders in the pharmaceutical industry and will play integral roles in the development and commercialization of the AgeneBio portfolio by providing strategic guidance as we continue to advance our product pipeline," says Dr. Michela Gallagher, founder and chief scientific officer of AgeneBio.

Mr. LePore has over 30 years of experience in the pharmaceutical industry, most recently as Chairman, CEO and President of Par Pharmaceuticals where he guided the company to a sale to Texas Pacific Group. His industry experience spans both the private and public sectors with board and operational experience in each, making him one of a handful of pharmaceutical executives with in depth knowledge of the brand, generic and pharmaceutical service industries.

"The development of a therapeutic to transform the management of Alzheimer's disease is desperately needed and yet potentially within reach, and I'm thrilled at the prospect of helping AgeneBio achieve that goal," said LePore.

Prior to joining AgeneBio, Mr. McLaughlin served as senior vice president and chief commercial officer of NuPathe Inc. through the company's sale to Teva Pharmaceuticals Industries Ltd. in 2014. At NuPathe, McLaughlin was responsible for preparing the organization for commercialization. In addition, he played an integral role in raising capital, including an initial public offering and corporate development initiatives that led to acquisition by Teva in a competitive M&A process. He has also held a variety of commercial leadership roles at Merck and Endo Pharmaceuticals with extensive experience launching new products, including several for central nervous system indications.

AgeneBio's lead product candidate, AGB101, a tablet taken once a day, is being developed to slow the progression of Alzheimer's disease from the time patients and their family members begin to notice issues with memory. This stage of Alzheimer's, called amnestic mild cognitive impairment, or aMCI, precedes the point where a patient experiences dementia and may be the ideal time to intervene with advancing disease process. There is compelling evidence that the part of the brain critical to creating new memories, the hippocampus, becomes overactive in patients with early Alzheimer's leading to decreased brain function and worsening of Alzheimer's symptoms. AGB101 slows activity in the hippocampus to restore normal brain function.

"The looming challenge of an aging population confronted by Alzheimer's is one of the largest and most frightening public health issues on the horizon, presenting a significant challenge and opportunity for companies like AgeneBio," said McLaughlin. "This is an exciting time to be joining the AgeneBio team as the company prepares to initiate a large-scale Phase II/III clinical trial for AGB101 in 2015."

Pending the results of a two year, large-scale clinical trial expected to be initiated by mid-2015 and subsequent regulatory submission, AGB101 could be the first FDA approved product indicated to slow the progression of Alzheimer's disease while improving patient memory.

About AgeneBio, Inc.

AgeneBio is developing therapeutics with the potential to preserve and restore cognitive function affected by a number of neurodegenerative diseases. AgeneBio's lead product candidate, AGB101, is being developed to slow progression of Alzheimer's disease and improve patient memory. Results from a Phase II study of AGB101 published in 2012 demonstrated restoration of normal brain function and improvement in memory in patients treated with AGB101 compared to placebo. The company is planning to initiate a Phase II/III clinical trial in mid-2015. Pending clinical trial results and FDA approval, AGB101 has the potential to be the first Alzheimer's therapeutic to not only improve memory but also to slow the progression of Alzheimer's disease.

The company also has a novel GABAA a5 small molecule program in late discovery stage with potential to address unmet needs for several diseases of the central nervous system including Alzheimer's disease, autism, and schizophrenia. The technology and patents behind AgeneBio's pipeline were discovered and initially developed by researchers at Johns Hopkins University, including the company's founder and chief scientific officer, Michela Gallagher, PhD.

Media Contact:
Hilary Lefebvre
Email Contact
(212) 300-4929

More Stories By Marketwired .

Copyright © 2009 Marketwired. All rights reserved. All the news releases provided by Marketwired are copyrighted. Any forms of copying other than an individual user's personal reference without express written permission is prohibited. Further distribution of these materials is strictly forbidden, including but not limited to, posting, emailing, faxing, archiving in a public database, redistributing via a computer network or in a printed form.

Latest Stories
So, you bought into the current machine learning craze and went on to collect millions/billions of records from this promising new data source. Now, what do you do with them? Too often, the abundance of data quickly turns into an abundance of problems. How do you extract that "magic essence" from your data without falling into the common pitfalls? In her session at @ThingsExpo, Natalia Ponomareva, Software Engineer at Google, provided tips on how to be successful in large scale machine learning...
In his session at @ThingsExpo, Kausik Sridharabalan, founder and CTO of Pulzze Systems, Inc., will focus on key challenges in building an Internet of Things solution infrastructure. He will shed light on efficient ways of defining interactions within IoT solutions, leading to cost and time reduction. He will also introduce ways to handle data and how one can develop IoT solutions that are lean, flexible and configurable, thus making IoT infrastructure agile and scalable.
SYS-CON Events announced today that Numerex Corp, a leading provider of managed enterprise solutions enabling the Internet of Things (IoT), will exhibit at the 19th International Cloud Expo | @ThingsExpo, which will take place on November 1–3, 2016, at the Santa Clara Convention Center in Santa Clara, CA. Numerex Corp. (NASDAQ:NMRX) is a leading provider of managed enterprise solutions enabling the Internet of Things (IoT). The Company's solutions produce new revenue streams or create operating...
DevOps and microservices are permeating software engineering teams broadly, whether these teams are in pure software shops but happen to run a business, such Uber and Airbnb, or in companies that rely heavily on software to run more traditional business, such as financial firms or high-end manufacturers. Microservices and DevOps have created software development and therefore business speed and agility benefits, but they have also created problems; specifically, they have created software sec...
To leverage Continuous Delivery, enterprises must consider impacts that span functional silos, as well as applications that touch older, slower moving components. Managing the many dependencies can cause slowdowns. See how to achieve continuous delivery in the enterprise.
SYS-CON Events announced today that Tintri Inc., a leading producer of VM-aware storage (VAS) for virtualization and cloud environments, will exhibit at the 19th International Cloud Expo, which will take place on November 1–3, 2016, at the Santa Clara Convention Center in Santa Clara, CA. Tintri VM-aware storage is the simplest for virtualized applications and cloud. Organizations including GE, Toyota, United Healthcare, NASA and 6 of the Fortune 15 have said “No to LUNs.” With Tintri they mana...
In his general session at 18th Cloud Expo, Lee Atchison, Principal Cloud Architect and Advocate at New Relic, discussed cloud as a ‘better data center’ and how it adds new capacity (faster) and improves application availability (redundancy). The cloud is a ‘Dynamic Tool for Dynamic Apps’ and resource allocation is an integral part of your application architecture, so use only the resources you need and allocate /de-allocate resources on the fly.
Fifty billion connected devices and still no winning protocols standards. HTTP, WebSockets, MQTT, and CoAP seem to be leading in the IoT protocol race at the moment but many more protocols are getting introduced on a regular basis. Each protocol has its pros and cons depending on the nature of the communications. Does there really need to be only one protocol to rule them all? Of course not. In his session at @ThingsExpo, Chris Matthieu, co-founder and CTO of Octoblu, walk you through how Oct...
IoT is fundamentally transforming the auto industry, turning the vehicle into a hub for connected services, including safety, infotainment and usage-based insurance. Auto manufacturers – and businesses across all verticals – have built an entire ecosystem around the Connected Car, creating new customer touch points and revenue streams. In his session at @ThingsExpo, Macario Namie, Head of IoT Strategy at Cisco Jasper, will share real-world examples of how IoT transforms the car from a static p...
Web Real-Time Communication APIs have quickly revolutionized what browsers are capable of. In addition to video and audio streams, we can now bi-directionally send arbitrary data over WebRTC's PeerConnection Data Channels. With the advent of Progressive Web Apps and new hardware APIs such as WebBluetooh and WebUSB, we can finally enable users to stitch together the Internet of Things directly from their browsers while communicating privately and securely in a decentralized way.
"My role is working with customers, helping them go through this digital transformation. I spend a lot of time talking to banks, big industries, manufacturers working through how they are integrating and transforming their IT platforms and moving them forward," explained William Morrish, General Manager Product Sales at Interoute, in this SYS-CON.tv interview at 18th Cloud Expo, held June 7-9, 2016, at the Javits Center in New York City, NY.
More and more companies are looking to microservices as an architectural pattern for breaking apart applications into more manageable pieces so that agile teams can deliver new features quicker and more effectively. What this pattern has done more than anything to date is spark organizational transformations, setting the foundation for future application development. In practice, however, there are a number of considerations to make that go beyond simply “build, ship, and run,” which changes ho...
The Internet of Things can drive efficiency for airlines and airports. In their session at @ThingsExpo, Shyam Varan Nath, Principal Architect with GE, and Sudip Majumder, senior director of development at Oracle, will discuss the technical details of the connected airline baggage and related social media solutions. These IoT applications will enhance travelers' journey experience and drive efficiency for the airlines and the airports. The session will include a working demo and a technical d...
Kubernetes is a new and revolutionary open-sourced system for managing containers across multiple hosts in a cluster. Ansible is a simple IT automation tool for just about any requirement for reproducible environments. In his session at @DevOpsSummit at 18th Cloud Expo, Patrick Galbraith, a principal engineer at HPE, discussed how to build a fully functional Kubernetes cluster on a number of virtual machines or bare-metal hosts. Also included will be a brief demonstration of running a Galera M...
Developing software for the Internet of Things (IoT) comes with its own set of challenges. Security, privacy, and unified standards are a few key issues. In addition, each IoT product is comprised of (at least) three separate application components: the software embedded in the device, the back-end service, and the mobile application for the end user’s controls. Each component is developed by a different team, using different technologies and practices, and deployed to a different stack/target –...